The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants
2020 · Nature Communications · 115 citations
https://doi.org/10.1038/s41467-020-14829-5
R
Rogier Mous
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
79
Papers
1.4K
Citations
16
h-index
22
i10-index
Rogier Mous is an academic researcher from Utrecht University. The author has contributed to research in topics: Chronic Lymphocytic Leukemia Research & Lymphoma Diagnosis and Treatment & CAR-T cell therapy research. The author has an h-index of 16, co-authored 68 publications.
Papers by this author
worksMinimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial
2022 · The Lancet Oncology · 56 citations
https://doi.org/10.1016/s1470-2045(22)00220-0
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial
2019 · Haematologica · 52 citations
https://doi.org/10.3324/haematol.2019.238162
Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA
2023 · Journal of Hematology & Oncology · 14 citations
https://doi.org/10.1186/s13045-023-01500-x
Hematologic malignancies following immune checkpoint inhibition for solid tumors
2022 · Cancer Immunology Immunotherapy · 11 citations
https://doi.org/10.1007/s00262-022-03230-4
ABCL-404: Epcoritamab + R-ICE in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Eligible For Autologous Stem Cell Transplantation (ASCT): EPCORE NHL-2
2025 · Clinical Lymphoma Myeloma & Leukemia · 2 citations
https://doi.org/10.1016/s2152-2650(25)02258-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat